Ikonisys’ OncoFISH breast cancer test
This article was originally published in The Gray Sheet
Executive Summary
Firm gains 510(k) clearance Oct. 28 for its OncoFISH non-invasive HER-2 gene test for breast cancer. The device is a "fully automated" microscopy application for determining HER-2 status with breast cancer specimens processed with Abbott's PathVysion HER-2 DNA probe kit, according to the company. The test is run on Ikonisys' CellOptics system. The presence of HER-2 gene amplification indicates whether a patient is a candidate for treatment with Genentech's Herceptin (trastuzumab)